Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care
November 07 2018 - 8:30AM
Daxor Corporation (NYSE MKT:
DXR), an investment company with innovative medical
instrumentation and biotechnology operations focused on blood
volume measurement, today announced that the U.S. Army has selected
it for a contract award to develop a blood volume analyzer for
improving combat casualty care.
The selection was made under the Defense
Department’s Small Business Innovative Research (SBIR)
program. The contract award will be to develop and
demonstrate a prototype blood volume analyzer suitable for military
use leveraging Daxor’s technology and experience with blood volume
measurement devices. “Hemorrhage is the primary cause of
death in about 30% of injured soldiers,” said Michael Feldschuh,
CEO of Daxor Corporation. “Direct blood volume measurement
has been shown to improve outcomes in a broad range of acute and
chronic medical conditions. Our existing technology platform
and patent portfolio is an ideal foundation for developing a rapid,
rugged, portable blood volume analyzer that can improve prehospital
resuscitation on the battlefield, potentially saving many
lives.”
"This is an exciting additional opportunity to
push our research and development program forward,” says Jonathan
Feldschuh, Chief Scientific Officer. “We are focused on
making volume measurement easier and quicker to perform, whether in
a hospital lab, on the battlefield, or at the patient bedside.”
This is a first-time award for Daxor. SBIR
contracts are designed to stimulate innovation by companies to
develop technologies and solutions that meet critical Army
needs. SBIR programs benefit the Department of Defense (DoD)
and the private sector and support the nation’s economic
growth.
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the first instrument approved by the
FDA to provide rapid direct measurement of a patient’s blood
volume. We believe that the BVA-100 Blood Volume Analyzer has
the potential to transform therapy in a broad range of surgical and
medical conditions. It is our goal, working in conjunction
with hospitals and clinics, to achieve that possibility.
Ultimately the company’s mission is to help hospitals and
physicians incorporate Daxor’s BVA-100 diagnostic to significantly
improve the quality of patient care. For more information
please visit our website at http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events
to differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when
made. Daxor does not assume any obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contact Information:
Investor Relations Contact:
Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024